Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.61%
#2 Luxxcoin Luxxcoin +45.05%
#3 ResearchCoin ResearchCoin +21.75%
#4 Reactive Network Reactive Network +20.82%
#5 Layer3 Layer3 +20.58%
#6 Orderly Network Orderly Network +16.63%
#7 Aria.AI Aria.AI +12.89%
#8 Bitgert Bitgert +10.56%
#9 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +9.40%
#10 KAITO KAITO +9.17%
Coin of the day
Resolv wstUSR Resolv wstUSR
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
CSL Limited CSL Limited

CSL Limited

CSL
Classement en actions #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Prix de l'action
$99.32
Capitalisation boursière
$48.20B
Changement (1 jour)
0.98%
Changement (1 an)
-32.14%
Pays
AU
Échange CSL Limited (CSL)

Catégorie

Healthcare
Bénéfices pour CSL Limited (CSL)
Bénéfices en Dec 2025 TTM : $1.61B
Selon les derniers rapports financiers de CSL Limited, les bénéfices actuels de l'entreprise sont de $1.61B. En 2024, l'entreprise a réalisé un bénéfice de $3.38B, une augmentation par rapport à celui de 2023 qui était de $2.66B. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour CSL Limited de 2000 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $1.61B -56.65%
2025 $3.72B 10.34%
2024 $3.38B 26.74%
2023 $2.66B -4.19%
2022 $2.78B -6.80%
2021 $2.98B 15.92%
2020 $2.57B 9.89%
2019 $2.34B 2.63%
2018 $2.28B 35.00%
2017 $1.69B 8.61%
2016 $1.56B -9.22%
2015 $1.71B 6.84%
2014 $1.60B 19.64%
2013 $1.34B 5.36%
2012 $1.27B -7.31%
2011 $1.37B 38.29%
2010 $992.87M 11.00%
2009 $894.45M 2.37%
2008 $873.74M 56.73%
2007 $557.47M 493.43%
2006 $93.94M -74.77%
2005 $372.39M 201.20%
2004 $123.64M 168.99%
2003 $45.96M -7.38%
2002 $49.63M -8.38%
2001 $54.17M 88.04%
2000 $28.81M 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.51B 1,170.24%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B 187.63%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B 224.03%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B 32.42%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -10.11%
NL